Decreased levels of synaptosomal associated protein 25 in the brain of patients with Down Syndrome and Alzheimer's disease

Synaptosomal associated protein 25 kDa (snap‐25) is a widely distributed membrane‐associated protein in the brain, mainly localized in nerve terminals. In nerve terminals, snap‐25 participates in docking and/or fusion of synaptic vesicles with the plasmalemma, a process essential for synaptic vesicle exocytosis. Recent work suggests a role in brain development, forming presynaptic sites by regulating axonal outgrowth and nerve growth‐induced neurite elongation. In Down syndrome (DS) brain, it is abnormally developed from early life, and brain pathology becomes even more pronounced when Alzheimer's disease (AD) develops in the fourth decade. This information led us to examine snap‐25 in the brain of patients with DS and AD. We studied snap‐25 and glial fibrillary acidic protein (GFAP) brain levels in five individual brain areas of 9 aged patients with DS, 9 patients with AD and 9 controls, applying two‐dimensional gel electrophoresis. Decreased snap‐25 levels were found in the five brain regions of the patients with DS and AD. Increased expression levels of GFAP were found in the frontal, parietal, temporal and occipital cortex regions of the DS and AD patients. Decreased snap‐25 protein levels in the brain of DS and AD may reflect impaired synaptogenesis or represent neuronal loss. Findings of increased GFAP, a marker for neuronal loss, along with data from literature would support the notion of decreased snap‐25 secondary to neuronal decay in both neurodegenerative disorders.

[1]  M. Marín‐Padilla,et al.  Pyramidal cell abnormalities in the motor cortex of a child with Down's syndrome. A Golgi study , 1976, The Journal of comparative neurology.

[2]  W. Catterall,et al.  Calcium-dependent interaction of N-type calcium channels with the synaptic core complex , 1996, Nature.

[3]  F E Bloom,et al.  The identification of a novel synaptosomal-associated protein, SNAP-25, differentially expressed by neuronal subpopulations , 1989, The Journal of cell biology.

[4]  F. Benfenati,et al.  Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin , 1992, Nature.

[5]  L. Becker,et al.  Dendrites, dementia and the down syndrome , 1989, Brain and Development.

[6]  N. Cairns,et al.  Similar deficits of central histaminergic system in patients with Down syndrome and Alzheimer disease , 1997, Neuroscience Letters.

[7]  N. Cairns,et al.  Evidence against increased oxidative DNA-damage in Down syndrome , 1997, Neuroscience Letters.

[8]  P. Burger,et al.  The development of the pathologic changes of Alzheimer's disease and senile dementia in patients with Down's syndrome. , 1973, The American journal of pathology.

[9]  J. Metso,et al.  Apolipoprotein A-IV polymorphism in the Finnish population: gene frequencies and description of a rare allele. , 1988, Human heredity.

[10]  N. Cairns,et al.  Excitatory amino acids and monoamines in parahippocampal gyrus and frontal cortical pole of adults with Down syndrome. , 1997, Life sciences.

[11]  D. Rouquié,et al.  New zwitterionic detergents improve the analysis of membrane proteins by two‐dimensional electrophoresis , 1998, Electrophoresis.

[12]  C. Duyckaerts,et al.  Accumulation of SNAP‐25 immunoreactive material in axons of Alzheimer's disease , 1997, Neuroreport.

[13]  T. Taniguchi,et al.  Differential involvement of synaptic vesicle and presynaptic plasma membrane proteins in Alzheimer's disease. , 1997, Biochemical and biophysical research communications.

[14]  N. Cairns,et al.  Increased kynurenic acid levels and decreased brain kynurenine aminotransferase I in patients with Down syndrome. , 1996, Life sciences.

[15]  V. Cowie,et al.  A STATISTICAL NOTE ON CEREBELLAR AND BRAIN‐STEM WEIGHT IN MONGOLISM , 2008 .

[16]  Paul Tempst,et al.  SNAP receptors implicated in vesicle targeting and fusion , 1993, Nature.

[17]  H. Langen,et al.  Identification of proteins by matrix-assisted laser desorption ionization-mass spectrometry following in-gel digestion in low-salt, nonvolatile buffer and simplified peptide recovery. , 1997, Analytical biochemistry.

[18]  W. Snow,et al.  The NINCDS‐ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease , 1988, Neurology.

[19]  J. Skene,et al.  The 25 kDa synaptosomal-associated protein SNAP-25 is the major methionine-rich polypeptide in rapid axonal transport and a major substrate for palmitoylation in adult CNS , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[20]  H. Rehder.  Pathology of trisomy 21--with particular reference to persistent common atrioventricular canal of the heart. , 1981, Human genetics. Supplement.

[21]  H. Langen,et al.  Effect of protein application mode and acrylamide concentration on the resolution of protein spots separated by two‐dimensional gel electrophoresis , 1997, Electrophoresis.

[22]  C. Epstein.  The Neurobiology of Down syndrome , 1986 .

[23]  A. Clark,et al.  Neuronal and Glial Gene Expression in Neocortex of Down's Syndrome and Alzheimer's Disease , 1993, Journal of neuropathology and experimental neurology.

[24]  M. Catsicas,et al.  Inhibition of axonal growth by SNAP-25 antisense oligonucleotides in vitro and in vivo , 1993, Nature.

[25]  H. Parnas,et al.  Voltage‐Dependent Interaction Between the Muscarinic ACh Receptor and Proteins of the Exocytic Machinery , 1997, The Journal of physiology.

[26]  K M Hahn,et al.  Differential expression of SNAP-25 protein isoforms during divergent vesicle fusion events of neural development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[28]  K. Wisniewski,et al.  Brain growth in Down syndrome subjects 15 to 22 weeks of gestational age and birth to 60 months. , 1990, Clinical neuropathology.

[29]  J. H. Chou,et al.  Tetanus toxin action: inhibition of neurotransmitter release linked to synaptobrevin proteolysis. , 1992, Biochemical and biophysical research communications.

[30]  J Clinton,et al.  Differential synaptic loss in the cortex in Alzheimer's disease: a study using archival material. , 1994, Neuroreport.

[31]  G. Augustine,et al.  Disruption of syntaxin-mediated protein interactions blocks neurotransmitter secretion. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Balázs,et al.  Neuronal plasticity and astrocytic reaction in Down syndrome and Alzheimer disease , 1990, Journal of the Neurological Sciences.

[33]  U. Boschert,et al.  Developmental and plasticity‐related differential expression of two SNAP‐25 isoforms in the rat brain , 1996, The Journal of comparative neurology.

[34]  L. Becker,et al.  Dendritic atrophy in children with Down's syndrome , 1986, Annals of neurology.

[35]  Paul J. Harrison,et al.  The relative importance of premortem acidosis and postmortem interval for human brain gene expression studies: selective mRNA vulnerability and comparison with their encoded proteins , 1995, Neuroscience Letters.